Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia

Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.